Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Millennium: The Takeda Oncology Company
Data Presented on Two Novel Millennium Investigational Oncology Drugs at ASCO
June 16th, 2009
Millennium: The Takeda Oncology Company reported the presentation of clinical and preclinical data on two of its oncology pipeline molecules, MLN4924 and MLN8237. MLN4924 is a small molecule aimed at inhibiting the NEDD8-Activating Enzyme (NAE), a Millennium-discovered target upstream of the proteasome. Data providing the preclinical rationale for the advancement of the molecule into clinical trials were recently published in the journal Nature (April 2009). MLN4924 is currently in Phase I clinical trials evaluating its use in the treatment of patients with both solid tumors and hematologic malignancies. MLN8237 is an oral compound designed to...
Source: Cancer Weekly (2009-06-16)
|
